RE:RE:RE:RE:Phase 1/2 AMBUSH Trial Blenrep also didn’t do much better at shrinking tumors, with a response rate of 41% compared with 36% for the control group. It so far also showed no benefit at preventing deaths.
At the time of the analysis, when 37.5% of the trial patients had died, Blenrep and control arms recorded median survival of 21.2 months and 21.1 months, respectively.
Patients on the GSK drug had a 14% higher risk of death.